Frederiksen, K. S., Boada, M., Frölich, L., Kramberger, M., Scarmeas, N., Vijverberg, E., . . . Jessen, F. (2026). Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: Comments on a Cochrane review by individual members of the EADC : short communication. The journal of prevention of Alzheimer's disease, 13(7), . https://doi.org/10.1016/j.tjpad.2026.100598
Style de citation Chicago (17e éd.)Frederiksen, Kristian Steen, et al. "Class-level Aggregation Obscures Clinically Relevant Heterogeneity in Anti-amyloid Antibody Trials: Comments on a Cochrane Review by Individual Members of the EADC : Short Communication." The Journal of Prevention of Alzheimer's Disease 13, no. 7 (2026). https://doi.org/10.1016/j.tjpad.2026.100598.
Style de citation MLA (9e éd.)Frederiksen, Kristian Steen, et al. "Class-level Aggregation Obscures Clinically Relevant Heterogeneity in Anti-amyloid Antibody Trials: Comments on a Cochrane Review by Individual Members of the EADC : Short Communication." The Journal of Prevention of Alzheimer's Disease, vol. 13, no. 7, 2026, https://doi.org/10.1016/j.tjpad.2026.100598.